Clinical Trial Update: HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating HRS-4642 in combination with Nimotuzumab and chemotherapy for borderline resectable pancreatic adenocarcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• HRS-4642
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Zhejiang University | Conditions: Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: RECRUITING